Exterior of Astellas’ United States office, where teams develop innovative therapies with integrity and patient-first focus.

United States newsroom

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.

Latest news

VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Jan 8, 2026

Read more VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses

Astellas and the Internet’s Favorite Grandma, Barbara ‘Babs’ Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA)

Oct 23, 2025

Read more Astellas and the Internet’s Favorite Grandma, Barbara ‘Babs’ Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA)

XTANDI^® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer

Oct 19, 2025

Read more XTANDI^® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer

Discover more

Return to global media homepage

U.S.

Follow U.S. news

Subscribe to news alerts